The development and approval process for orphan drugs often involves various incentives provided by regulatory agencies. In the United States, the FDA offers benefits such as tax credits, grant funding, and a seven-year market exclusivity period upon approval. In the European Union, the EMA provides similar incentives, including protocol assistance and ten years of market exclusivity.
